BLS Pharmaceuticals Limited (ASX:BLS)
1.180
-0.025 (-2.07%)
Sep 22, 2026, 4:10 PM AEST
BLS Pharmaceuticals Ratios and Metrics
Market cap in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 278 | 213 | 89 | 10 | 38 | 8 | |
Market Cap Growth | 211.66% | 140.05% | 767.35% | -73.09% | 395.11% | -57.14% |
Enterprise Value | 273 | 211 | 87 | 8 | 34 | 6 |
Last Close Price | 1.21 | 0.93 | 0.41 | 0.05 | 0.20 | 0.12 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 17.99 | 13.84 | 18.11 | - | - | - |
PS Ratio | 3.75 | 2.88 | 3.03 | 1.06 | 7.18 | 16.57 |
PB Ratio | 8.93 | 6.85 | 7.33 | 3.10 | 2.53 | -21.05 |
P/TBV Ratio | 8.96 | 6.88 | 7.15 | 2.84 | 10.66 | - |
P/FCF Ratio | 172.74 | 132.62 | 21.09 | - | - | - |
P/OCF Ratio | 51.25 | 39.35 | 14.14 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 3.69 | 2.85 | 2.99 | 0.88 | 6.45 | 12.19 |
EV/EBITDA Ratio | 13.09 | 10.47 | 10.91 | - | - | - |
EV/EBIT Ratio | 13.95 | 10.79 | 11.33 | - | - | - |
EV/FCF Ratio | 169.72 | 131.23 | 20.79 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.27 | 0.27 | 0.13 | 0.22 | 0.04 | -1.09 |
Debt / EBITDA Ratio | 0.40 | 0.40 | 0.18 | - | - | - |
Debt / FCF Ratio | 5.25 | 5.25 | 0.36 | - | - | - |
Net Debt / Equity Ratio | -0.16 | -0.16 | -0.51 | -0.10 | -0.22 | -0.91 |
Net Debt / EBITDA Ratio | -0.24 | -0.24 | -0.76 | 0.29 | 1.92 | -0.78 |
Net Debt / FCF Ratio | -3.02 | -3.02 | -1.46 | 0.09 | 2.76 | -0.58 |
Asset Turnover | 2.06 | 2.06 | 2.23 | 0.79 | 0.58 | 0.30 |
Inventory Turnover | 3.22 | 3.22 | 4.26 | 3.78 | 6.98 | 1.48 |
Quick Ratio | 1.50 | 1.50 | 1.59 | 0.78 | 1.81 | 0.39 |
Current Ratio | 2.90 | 2.90 | 2.46 | 1.92 | 2.25 | 0.49 |
Return on Equity (ROE) | 71.30% | 71.30% | 63.64% | -141.75% | -26.18% | -62.97% |
Return on Assets (ROA) | 34.10% | 34.10% | 36.72% | -5.80% | -12.53% | -18.13% |
Return on Capital Employed (ROCE) | 51.60% | 51.60% | 58.60% | -29.90% | -12.10% | 122.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 5.55% | 7.23% | 5.52% | -130.21% | -5.10% | -6.43% |
FCF Yield | 0.58% | 0.75% | 4.74% | -36.53% | -3.13% | -7.38% |
Buyback Yield / Dilution | -6.91% | -6.91% | -11.36% | -43.61% | -83.52% | -14.42% |